195 related articles for article (PubMed ID: 36569876)
1. Body composition parameters for predicting the efficacy of neoadjuvant chemotherapy with immunotherapy for gastric cancer.
Lin GT; Huang JB; Lin JL; Lin JX; Xie JW; Wang JB; Lu J; Zheng CH; Huang CM; Li P
Front Immunol; 2022; 13():1061044. PubMed ID: 36569876
[TBL] [Abstract][Full Text] [Related]
2. Visceral adiposity and inflammatory bowel disease.
Rowan CR; McManus J; Boland K; O'Toole A
Int J Colorectal Dis; 2021 Nov; 36(11):2305-2319. PubMed ID: 34104989
[TBL] [Abstract][Full Text] [Related]
3. Body composition parameters predict pathological response and outcomes in locally advanced gastric cancer after neoadjuvant treatment: A multicenter, international study.
Lin JX; Tang YH; Zhou WX; Desiderio J; Parisi A; Xie JW; Wang JB; Cianchi F; Antonuzzo L; Borghi F; Lu J; Chen QY; Cao LL; Lin M; Tu RH; Staderini F; Marano A; Peluso C; Li P; Zheng CH; Ma YB; Huang CM
Clin Nutr; 2021 Aug; 40(8):4980-4987. PubMed ID: 34364237
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of neoadjuvant immunotherapy in resectable gastric/gastroesophageal junction tumors: a meta-analysis and systematic review.
Wang J; Tong T; Zhang G; Jin C; Guo H; Liu X; Zhang Z; Li J; Zhao Y
Front Immunol; 2024; 15():1339757. PubMed ID: 38352873
[TBL] [Abstract][Full Text] [Related]
5. Changes in skeletal muscle and adipose tissue during cytotoxic chemotherapy for testicular germ cell carcinoma and associations with adverse events.
Phuong A; Marquardt JP; O'Malley R; Holt SK; Laidlaw G; Eagle Z; Ngo S; Orcutt D; Schade GR; Lin DW; Schweizer MT; Yezefski T; Yu EY; Montgomery B; Grivas P; Fintelmann FJ; Psutka SP
Urol Oncol; 2022 Oct; 40(10):456.e19-456.e30. PubMed ID: 36028450
[TBL] [Abstract][Full Text] [Related]
6. Body Composition Changes in Gastric Cancer Patients during Preoperative FLOT Therapy: Preliminary Results of an Italian Cohort Study.
Rinninella E; Strippoli A; Cintoni M; Raoul P; Vivolo R; Di Salvatore M; Genco E; Manfredi R; Bria E; Tortora G; Gasbarrini A; Pozzo C; Mele MC
Nutrients; 2021 Mar; 13(3):. PubMed ID: 33809587
[TBL] [Abstract][Full Text] [Related]
7. Combined systemic immune-inflammatory index (SII) and prognostic nutritional index (PNI) predicts chemotherapy response and prognosis in locally advanced gastric cancer patients receiving neoadjuvant chemotherapy with PD-1 antibody sintilimab and XELOX: a prospective study.
Ding P; Guo H; Sun C; Yang P; Kim NH; Tian Y; Liu Y; Liu P; Li Y; Zhao Q
BMC Gastroenterol; 2022 Mar; 22(1):121. PubMed ID: 35287591
[TBL] [Abstract][Full Text] [Related]
8. [Effect of neoadjuvant chemotherapy on nutritional status of locally advanced gastric cancer].
Deng G; Qu J; Zhai S; Shi Y; Wang X
Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Mar; 21(3):331-335. PubMed ID: 29577223
[TBL] [Abstract][Full Text] [Related]
9. Changes in Lean Muscle Mass Associated with Neoadjuvant Platinum-Based Chemotherapy in Patients with Muscle Invasive Bladder Cancer.
Rimar KJ; Glaser AP; Kundu S; Schaeffer EM; Meeks J; Psutka SP
Bladder Cancer; 2018 Oct; 4(4):411-418. PubMed ID: 30417052
[TBL] [Abstract][Full Text] [Related]
10. [Safety and effectiveness of oxaliplatin combined with capecitabine or oxaliplatin combined with S-1 neoadjuvant chemotherapy in the treatment of advanced gastric cancer].
Xie BW; Zang L; Ma JJ; Sun J; Yang X; Wang ML; Lu AG; Hu WG; Zheng MH
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):138-144. PubMed ID: 33508919
[No Abstract] [Full Text] [Related]
11. Impact of skeletal muscle mass in patients with unresectable gastric cancer who received palliative first-line chemotherapy based on 5-fluorouracil.
Matsunaga T; Saito H; Miyauchi W; Shishido Y; Miyatani K; Morimoto M; Murakami Y; Hanaki T; Kihara K; Yamamoto M; Tokuyasu N; Takano S; Sakamoto T; Hasegawa T; Fujiwara Y
BMC Cancer; 2021 Nov; 21(1):1219. PubMed ID: 34774016
[TBL] [Abstract][Full Text] [Related]
12. Impact of body composition on clinical outcomes in people with gastric cancer undergoing radical gastrectomy after neoadjuvant treatment.
Zhang Y; Li Z; Jiang L; Xue Z; Ma Z; Kang W; Ye X; Liu Y; Jin Z; Yu J
Nutrition; 2021 May; 85():111135. PubMed ID: 33556785
[TBL] [Abstract][Full Text] [Related]
13. No influence of sarcopenia on survival of ovarian cancer patients in a prospective validation study.
Ubachs J; Koole SN; Lahaye M; Fabris C; Bruijs L; Schagen van Leeuwen J; Schreuder HWR; Hermans RH; de Hingh IH; van der Velden J; Arts HJ; van Ham M; van Dam P; Vuylsteke P; Bastings J; Kruitwagen RFPM; Lambrechts S; Olde Damink SWM; Rensen SS; Van Gorp T; Sonke GS; van Driel WJ
Gynecol Oncol; 2020 Dec; 159(3):706-711. PubMed ID: 33019981
[TBL] [Abstract][Full Text] [Related]
14. Impact of body composition, grip strength, and physical performance on clinical outcomes for locally advanced gastric cancer during neoadjuvant chemotherapy: A prospective cohort study.
Zhou D; Zuo J; Zeng C; Zhang L; Gao X; Li G; Wang X
Nutrition; 2024 Apr; 125():112472. PubMed ID: 38810532
[TBL] [Abstract][Full Text] [Related]
15. [Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors].
Ouyang GL; Meng WJ; Shu P; Deng XB; Wu B; Jiang D; Zhuang H; Shen YL; Zhou ZG; Wang ZQ; Wang X
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr; 22(4):349-356. PubMed ID: 31054549
[No Abstract] [Full Text] [Related]
16. Association between body composition, survival, and toxicity in advanced esophagogastric cancer patients receiving palliative chemotherapy.
Dijksterhuis WPM; Pruijt MJ; van der Woude SO; Klaassen R; Kurk SA; van Oijen MGH; van Laarhoven HWM
J Cachexia Sarcopenia Muscle; 2019 Feb; 10(1):199-206. PubMed ID: 30666831
[TBL] [Abstract][Full Text] [Related]
17. Prediction of hematologic toxicity in luminal type breast cancer patients receiving neoadjuvant chemotherapy using CT L1 level skeletal muscle index.
Chen M; Wang P; Li Y; Jin Z; An Y; Zhang Y; Yuan W
Sci Rep; 2024 Apr; 14(1):8604. PubMed ID: 38615057
[TBL] [Abstract][Full Text] [Related]
18. Correlation between Skeletal Muscle Mass and Adverse Events of Neoadjuvant Chemotherapy in Patients with Gastric Cancer.
Matsuura N; Motoori M; Fujitani K; Nishizawa Y; Komatsu H; Miyazaki Y; Miyazaki S; Tomokuni A; Komori T; Iwase K
Oncology; 2020; 98(1):29-34. PubMed ID: 31509833
[TBL] [Abstract][Full Text] [Related]
19. Body composition parameters correlate with the endoscopic severity in Crohn's disease patients treated with infliximab.
Tang W; Xie G; Li J; Tan W; Yi R; Yang L; Zhang L; Deng J; Zhang Y; Li K
Front Nutr; 2023; 10():1251448. PubMed ID: 37674885
[TBL] [Abstract][Full Text] [Related]
20. Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab.
Masuda K; Shoji H; Nagashima K; Yamamoto S; Ishikawa M; Imazeki H; Aoki M; Miyamoto T; Hirano H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Boku N
BMC Cancer; 2019 Oct; 19(1):974. PubMed ID: 31638948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
